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OBJECTIVES We hypothesized that aspirin (ASA) might alter the beneficial effect of beta-blockers on left
ventricular ejection fraction (LVEF) in patients with chronic heart failure.
BACKGROUND Aspirin blunts the vasodilation caused by both angiotensin-converting enzyme (ACE)
inhibitors and beta-blockers in hypertensive patients and in patients with heart failure. Several
studies suggest that ASA also blunts some of beneficial effects of ACE inhibitors on mortality
in patients with heart failure. To our knowledge, there have been no data evaluating the
possible interaction of ASA and beta-blockers on left ventricular remodeling in patients with
heart failure.
METHODS We retrospectively evaluated patients entered into the Multicenter Oral Carvedilol Heart
failure Assessment (MOCHA) trial, a 6-month, double-blind, randomized, placebo-
controlled, multicenter, dose-response evaluation of carvedilol in patients with chronic stable
symptomatic heart failure. Multivariate analysis was performed to determine if aspirin
independently influenced the improvement in LVEF.
RESULTS Over all randomized patients (n  293), LVEF improved 8.2  0.8 ejection fraction (EF)
units in ASA nonusers and 4.5  0.7 EF units in ASA users (p  0.005). In subjects
randomized to treatment with carvedilol (n  231), LVEF improved 9.5  0.9 EF units in
ASA nonusers and 5.8  0.8 EF units in ASA users (p  0.02). In subjects randomized to
treatment with placebo (n  62), LVEF improved 2.8  1.2 EF units in ASA nonusers and
0.5 1.4 EF units in ASA users (p 0.20). Aspirin did not significantly affect the heart rate
or systolic blood pressure response in either the placebo or carvedilol groups. The effect of
ASA became more significant on multivariate analysis. The change in LVEF was also
influenced by carvedilol dose, etiology of heart failure, baseline heart rate, EF and coumadin
use. The detrimental effect of ASA on the improvement in LVEF was dose-related and was
present in both placebo and carvedilol groups, although the effect was statistically significant
only in the much larger carvedilol group.
CONCLUSIONS Aspirin significantly affects the changes in LVEF over time in patients with heart failure and
systolic dysfunction treated with carvedilol. The specific mechanism(s) underlying this
interaction are unknown and further studies are needed to provide additional understanding
of the molecular basis of factors influencing reverse remodeling in patients with heart failure.
(J Am Coll Cardiol 2001;38:1950–6) © 2001 by the American College of Cardiology
Considerable controversy exists as to whether aspirin (ASA)
blocks some of the beneficial effects of angiotensin-
converting enzyme (ACE) inhibitors in patients with
chronic heart failure (1). Several studies demonstrate that
ASA attenuates the acute hypotensive effects of ACE
inhibitors in patients with hypertension as well as the acute
vasodilator effect of ACE inhibitors in patients with heart
failure (2–6). Retrospective analyses of both the Studies Of
Left Ventricular Dysfunction (SOLVD) study and Coop-
erative New Scandinavian Enalapril Survival Study II sug-
gested either absent or reduced beneficial effects, respec-
tively, of enalapril in patients taking ASA (7,8). However,
other studies have not demonstrated an interaction between
ACE inhibitors and ASA (9–12). To our knowledge, no
other studies have evaluated whether there is an interaction
between ASA and beta-blockers in patients with heart
failure. It is known that ASA attenuates the hypotensive but
not the negative inotropic or chronotropic effects of beta-
blockers and it has been suggested that this effect may be
prostaglandin (PG)-mediated (13). We postulated that
ASA might interact with beta-adrenergic blockers in pa-
tients with chronic heart failure. As an improvement in left
ventricular ejection fraction (LVEF) is a consistent thera-
peutic benefit in patients with heart failure treated with
beta-blockers, we evaluated the effect of ASA on the
improvement in LVEF in patients who had participated in
the Multicenter Oral Carvedilol Heart failure Assessment
(MOCHA) trial, a study that compared multiple doses of
carvedilol to placebo in patients with heart failure and
systolic dysfunction.
METHODS
The MOCHA trial was a six-month, double-blind, placebo-
controlled, randomized, multicenter, dose-response evaluation
of carvedilol in 345 patients with chronic stable symptomatic
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heart failure (14). Patients were randomized uniformly into
four groups: 1) placebo, 2) low-dose carvedilol (6.25 mg twice
daily), 3) medium-dose carvedilol (12.5 mg twice daily) and 4)
high-dose carvedilol (25 mg twice daily). The specific methods
and results of this trial have been reported (14). Patients
underwent a baseline radionuclide LVEF during a three-week
screening phase when eligibility for the study was determined.
Once eligibility was determined and informed consent given,
patients underwent a two-week challenge phase consisting of
an initial dose of 6.25 mg twice daily of carvedilol. This dose
could be decreased to 3.125 mg twice daily as necessary for
symptoms of hypotension or worsening heart failure; if the
dose was initially decreased to 3.125 mg twice daily, it was
increased to 6.2 mg twice daily in the second week of the
challenge phase. Patients must have tolerated the 6.25-mg
twice daily dose to be randomized. Up-titration of carvedilol
was carried out on a weekly basis and most patients reached
maximum dose in two weeks, although patients having diffi-
culty could take four weeks to reach a maximum dose.
Following the up-titration phase, there was a six-month
maintenance phase. The radionuclide LVEF was repeated at
the end of the maintenance phase.
According to study design, all patients were between 18
and 85 years of age and had an LVEF of 35% with
symptomatic heart failure of either ischemic or nonischemic
etiology. The patients had to have symptoms of heart failure
for at least three months and a 6-min walk test of 150 m to
425 m (revised upward to 150 m to 450 m by protocol
amendment six months into the study). A resting heart rate
of 68 beats/min in the sitting position was required for
study participation.
All randomized patients who had evaluable ejection
fraction (EFs) at baseline and end of study (n  293) were
evaluated. Inter-LVEF intervals averaged 8 months, rang-
ing from 4 to 12 months, with 280 of the 293 intervals
(96%) from 7 to 9 months. Patients were compared accord-
ing to dose of ASA taken at baseline. Determinations of all
baseline medications were from the MOCHA file of current
medications and identified by drug code.
All analyses were performed with SAS software (SAS
Institute, Cary, North Carolina). Statistical significance was
set at a two-sided alpha  0.05. Unless otherwise specified,
data are presented as mean  SEM. Baseline comparisons
of ASA nonusers and users was by chi-square test and
unpaired t test. Bivariate comparisons of changes in LVEF,
heart rate (HR) and systolic blood pressure, between ASA
nonusers and users, broken down by carvedilol use and
etiology (ischemic vs. nonischemic), were by unpaired t test
or Wilcoxon Rank Sum test. The primary end point in
analysis was the change in LVEF. The multivariate design,
though balanced by etiology and carvedilol dose, was un-
balanced by ASA use, as might be expected in a retrospec-
tive analysis. To analyze the effect of ASA dose, controlling
the effects of etiology and carvedilol dose, multivariate
analyses were performed, using the general linear model
procedure of SAS. Adjusted means (as would be expected
had the design been balanced) and their standard errors
were calculated with the LSMEANS statement.
The multiple linear regression initially considered 18
predictor variables having theoretical plausibility: duration
of congestive heart failure, baseline systolic blood pressure
and all variables listed in Table 1, as well as ASA usage in
milligrams per day. Additional current medications were
treated as binary variables. For the predictors of primary
interest (ischemic etiology, carvedilol dose, ASA dose), the
four interactions were also included. Predictor variables
were removed from the model in stepwise backwards
elimination fashion, using the least significant criterion with
alpha  0.05.
Expected positive correlation between ASA use and
ischemic etiology and possible correlation between ASA use
and carvedilol dose raised multicollinearity (MCL) (high
linear dependence among one or more independent vari-
ables) concerns. Diagnostics used for MCL were the biva-
riate correlation coefficient, the variance inflation factor and
the condition index (15,16). Values suggesting MCL are
variance inflation factor  10 and condition index  30
(16).
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ASA  aspirin
EF  ejection fraction
HR  heart rate
LVEF  left ventricular ejection fraction
MCL  multicollinearity
MOCHA  Multicenter Oral Carvedilol Heart failure
Assessment
PG  prostaglandins
Table 1. Demographics
ASA
Nonusers
ASA
Users
p
Value
Descriptor
n 178 115
Age (yr) 58 1 62 1 0.002
Heart rate (beats/min) 84 1 80 1 0.02
Gender (% male) 72 83 0.046
NYHA II/III/IV (%) 48/49/3 47/52/1 0.50
Cause of CHF (% ischemic) 34 75 0.001
Race (% white) 74 83 0.07
Carvedilol dose (%)
0/6.25/12.5/25 mg twice daily
19/30/25/26 25/18/26/30 0.11
EF (EF units) 23 1 24 1 0.39
Current medications (%)
ACE inhibitors 96 89 0.02
Digoxin 93 90 0.35
Loop diuretics 96 97 0.67
Thiazide diuretics 22 20 0.62
Vasodilators 46 65 0.001
Coumadin 75 23 0.001
Calcium channel blockers 1 2 0.33
ACE  angiotensin-converting enzyme; ASA  aspirin; CHF  congestive heart
failure; EF  ejection fraction; NYHA  New York Heart Association.
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RESULTS
Table 1 gives important baseline descriptors of the patients.
There were 231 patients randomized to treatment with
carvedilol and 62 patients randomized to treatment with
placebo: 178 were ASA nonusers and 115 were ASA users.
The ASA nonusers were younger than ASA users (58  1
year vs. 62  1 year, p  0.002) and had a higher resting
HR (84  1 beats/min vs. 80  1 beats/min, p  0.02).
Systolic blood pressure was not different, averaging
115 mm Hg. The LVEF was not different, averaging 23 EF
units.
More of the ASA users were male (83% vs. 72%, p 
0.05) and had an ischemic etiology of HF (75% vs. 34%,
p  0.001). Percentages of patients in New York Heart
Association classes II, III and IV did not differ. Background
medical therapy is also shown in Table 1. Most patients
were taking ACE inhibitors, loop diuretics and digoxin.
The ACE inhibitors were used slightly less often in ASA
users than in nonusers (89% vs. 96%, p 0.02). More of the
ASA users were taking vasodilators, including nitrates (65%
vs. 46%, p  0.001). Twenty-three percent of the ASA
users were taking coumadin compared to 75% of the
non-ASA users (p  0.001).
Change in LVEF in ASA nonusers and users is shown in
Figure 1. The LVEF improved by 8.2 EF units in the ASA
nonusers and by 4.5 EF units in the ASA users (p 0.005).
In the carvedilol group, ASA nonusers had a 9.5-EF unit
increase compared to a 5.8-EF unit increase in the ASA
users (p  0.02). In the placebo group, LVEF improved by
2.8 EF units in the ASA nonusers compared to a 0.5-EF
unit increase in the ASA users (p  0.20)
Change in HR is shown in Figure 2. Overall patients’
HRs decreased 11 beats/min with no differences according
to ASA use. The HR decreased 14 beats/min in the
carvedilol-treated patients and 2 beats/min in the placebo-
treated patients; there were no differences in the ASA users
versus nonusers. Systolic blood pressure showed no signifi-
cant differences according to ASA use (Fig. 3). In Figure 3,
the interaction of carvedilol use (placebo, carvedilol) and
ASA use (no ASA, ASA) was not significant.
Mean values of the change in LVEF were further broken
down by etiology (ischemic vs. nonischemic) and treatment
group (carvedilol vs. placebo) and are shown in Table 2.
Although no significant differences by aspirin use resulted,
ASA users had a consistently lower improvement in LVEF
compared to nonusers, by 1.6 to 2.5 EF units.
Results of multiple linear regression are shown in Table 3.
In this Table, “b value” gives the change in LVEF for each
unit change in the associated predictor, while controlling
the effect of all other predictor variables. Thus, ASA dose is
significant at p  0.0005, with an expected decrease of 0.5
EF units in LVEF for each increase of aspirin dose of 81
mg/d. Ischemic etiology is significantly associated with a
decrease of 3.4 EF units, relative to nonischemic etiology.
Effects shown in Table 3 are additive. For example, an
ischemic subject taking 325 mg/d of ASA is expected to
have a change in LVEF that is 5.4 (3.4 4 0.5) EF units
lower than a nonischemic subject not taking ASA. In Table
3, only three variables have significance stronger than
marginal: ischemic etiology, carvedilol dose and ASA dose.
None of the four interactions of these variables was signif-
icant, the strongest being the interaction of ischemic etiol-
ogy and carvedilol dose (p  0.07). These results are
consistent with the results of the analysis of LVEF in the
MOCHA trial, which showed a dose-response relationship
of carvedilol dose and LVEF (p  0.001) and showed that
the response was stronger for nonischemic etiology than for
ischemic etiology (p  0.068) (14). In Table 3, b for
baseline LVEF is negative and b for baseline HR is positive,
consistent with a theorized normalizing action of carvedilol:
Figure 1. Changes in left ventricular ejection fraction (LVEF) in all patients, in carvedilol-treated patients and in placebo-treated patients.
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a lower baseline LVEF or a higher baseline HR results in
greater benefit of carvedilol. Out of concern for MCL,
regression diagnostics (maximum absolute value bivariate
correlation coefficient, maximum variance inflation factor,
maximum condition index) were used. For the model with
six independent variables (Table 3), the values were 0.31,
1.17 and 1.61, respectively. For the model with three
independent variables (ischemic etiology, carvedilol dose,
ASA dose), the values were 0.13, 1.03 and 1.20, respec-
tively. None of these diagnostic values indicates the presence
of MCL. Figure 4 shows graphically the results of multiple
regression analyses of change in LVEF on carvedilol dose
and ASA use, separately by ischemic etiology. The slopes
are nearly equal, with change in LVEF being about 3 EF
units less for ischemic etiology than for nonischemic etiol-
ogy, consistent with the MOCHA findings (14).
DISCUSSION
This study shows that in heart failure patients taking
carvedilol, LVEF improves less in patients taking ASA than
in patients not taking ASA. This result is not simply due to
the greater use of ASA in patients with an ischemic etiology
as multivariate analyses show that the negative effect of
ASA is independent of the negative effect of ischemic
etiology, with this independent effect validated by the
Figure 2. Changes in heart rate. Groups as in Figure 1.
Figure 3. Changes in systolic blood pressure. Groups as in Figure 1.
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absence of MCL in the model. Further, the effect of ASA
was dose-related.
From Table 3, the effect of ischemic etiology on the
change in LVEF is 3.4 EF units and the effect of ASA at
325 mg/d on the change in LVEF is calculated to be 2.0
EF units, about half the effect of ischemic etiology and
biologically important. Expressed as ratios, the effects of
ASA correspond to 20% to 30% reductions in the beneficial
effect of carvedilol. Etiology of heart failure, ASA dose and
carvedilol dose were all strong predictors of the change in
LVEF and test results for interaction among these variables
were nonsignificant. It is important to note that the com-
bination of carvedilol and ASA appears to limit but not
prevent an improvement in LVEF.
The apparent effect of ASA on change in LVEF in
patients taking placebo was unanticipated. Although this effect
was not significant, it was similar to the change seen in
carvedilol-treated patients. For placebo-treated patients as a
separate group, the smaller change in LVEF and the smaller n
reduced the statistical significance of the effect of ASA, making
it equivocal. Further studies evaluating changes in LVEF and
ASA in the absence of beta-blockers are warranted.
Potential mechanisms. There are two explanations for the
finding the LVEF improved less with carvedilol in patients
taking ASA. Aspirin may interfere with a mechanism of
benefit of carvedilol on LVEF. Conversely, ASA and
carvedilol might share a mechanism for some of the bene-
ficial effect in LVEF, so that some improvement in EF
would have already occurred in the patients taking ASA,
leaving less potential for improvement in LVEF with
carvedilol. Data in hypertensive patients suggest that ASA
blunts the hypotensive but not the negative inotropic and
chronotropic effects of beta-blockers (13). Indeed in the
present study, ASA use had no effect on the substantial
negative chronotropic effect of carvedilol. While there was a
trend for ASA use to have a positive effect on change in
systolic blood pressure in carvedilol-treated patients and a
negative effect in placebo-treated patients (Fig. 3), this
interaction was not significant. Data on systemic vascular
resistance were not available.
There are at least three potential mechanisms of interac-
tion between carvedilol and ASA in patients with heart
failure. Recently it has been shown that treatment with
beta-blockers in patients with hypertension and heart failure
is associated with an elevation in natriuretic peptides which
would be likely to have a beneficial effect promoting reverse
myocardial remodeling (17–19). This effect is not simply a
result of myocardial stretching and has been postulated to be
a mechanism by which beta-adrenergic blockers may result
in improvements in myocardial function (19,20). Natriuretic
peptides are released by prostaglandin F2 in isolated cardiac
myocytes (21,22). Aspirin, by preventing the synthesis of
prostaglandin F2, could diminish the release of natriuretic
peptides caused by beta-blockers limiting one potential
beneficial effect of carvedilol on LVEF. If this interaction is
operative, ASA might block some of the potential benefit of
carvedilol on LVEF.
A second possible site of interaction is at the sympathetic
nerve terminal. It is known that the bradykinin-stimulated
release of norepinephrine from cardiac sympathetic nerves is
inhibited by cyclo-oxygenase inhibition (23–25). Bradykinin
levels are increased in heart failure patients taking ACE
inhibitors (26,27). Aspirin, through cyclo-oxygenase inhi-
bition, might diminish bradykinin-mediated cardiac sympa-
thetic activity limiting another potential benefit of beta-
Figure 4. Change with left ventricular ejection fraction (LVEF) in aspirin
users and nonusers.
Table 3. Multivariate Analysis of Factors Influencing the
Change in LVEF
Predictor Unit b Value p Value
Ischemic etiology — 3.38 0.0002
Carvedilol dose 6.25 mg twice daily 1.91 0.0001
Aspirin dose 81 mg every day 0.51 0.0005
Baseline LVEF 10 EF U 1.45 0.03
Baseline HR 10 beats/min 0.70 0.04
Use of coumadin — 2.34 0.03
EF  ejection fraction; HR  heart rate; LVEF  left ventricular ejection fraction.
Table 2. Changes in Left Ventricular Ejection Fraction by
Etiology, Carvedilol Use and ASA Use
n
Changes
in EF
Units
p
Value
Difference
in ASA
Users vs.
Nonusers
Ischemia
Placebo
ASA Nonusers 15 0.9  2.0 0.45 2.0
ASA Users 17 1.1  1.6
Carvedilol
ASA Nonusers 45 7.6  1.3 0.09 2.5
ASA Users 69 5.2  0.8
Nonischemia
Placebo
ASA Nonusers 18 4.4  1.2 0.49 1.6
ASA Users 12 2.7  2.3
Carvedilol
ASA Nonusers 100 10.3  1.1 0.57 1.6
ASA Users 17 8.6  2.3
ASA  aspirin; EF  ejection fraction.
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blockers. Indeed Wang (28) has shown an enhanced renal
sympathetic nerve activity in response to epicardial brady-
kinin administration in a dog model of heart failure. The
bradykinin-enhanced renal sympathetic nerve activity was
decreased by cyclo-oxygenase inhibition. In this situation,
ASA might cause an improvement in LVEF in patients
with heart failure by decreasing cardiac sympathetic nerve
activity, leaving less room for a benefit of carvedilol in
blocking cardiac beta-adrenergic receptors.
A third potential site of interaction occurs because ASA
and beta-blockers inhibit renin release, especially in clinical
situations such as heart failure in which renin is activated
(18,29,30). It is possible that ASA lowers renin levels, thus
reducing the magnitude of the beneficial effect of beta-
blockers on renin. In this case, as in the previous situation,
ASA would have already provided some the benefit of
carvedilol on LVEF.
The present study cannot determine the mechanism for
the interaction of ASA and beta-blockers on LVEF. We
also cannot determine if ASA and carvedilol share a
common beneficial effect on LVEF or if ASA blocks a
beneficial effect of carvedilol. However, one previous study
as well as our own study suggest that ASA and carvedilol
may share a common mechanism of benefit. In a retrospec-
tive analysis of the Captopril And Thrombolysis Study
(CATS), Oosterga et al. (12) found that ASA alone reduced
left ventricular dilation independently of ACE inhibitors.
This finding suggests that ASA alone may result in bene-
ficial effects on LVEF. Although not statistically significant,
in this study there was a trend for less improvement in
LVEF in the placebo group in the ASA users than in the
non-ASA group. This might also suggest these patients had
already had a beneficial effect of ASA on LVEF. To our
knowledge, this the first study to describe an interaction
between ASA and beta-blockers in ventricular remodeling.
This interaction was strong and was enhanced in a multi-
variate analysis. The mechanism by which beta-blockers
improve myocardial function in patients with heart failure is
unknown. Further investigation of the interaction between
beta-blockers and ASA may shed light on the mechanism(s)
of myocardial remodeling (31).
Impact on mortality. This study was too small to assess the
effect that ASA might have on the improved mortality seen
with carvedilol. It is not clear if an improvement in LVEF
with beta-blockers could be used as a surrogate for the
mortality benefit, although data from Cardiac Insufficiency
Bisoprolol Study suggests that this may be the case (32).
Our study suggests that a dose of 325 mg/d of ASA might
result in 2 EF units less in improvement with carvedilol.
This small difference in EF has been associated with a
difference in mortality (14,33). However, even if the im-
provement in LVEF is etiologic in the benefits of beta-
blockers on mortality, other beneficial effects of ASA may
have a balancing effect on mortality. Thus, it is not possible
to conclude that aspirin might limit the beneficial mortality
effect of beta-blockers in patients with heart failure.
Aspirin dose. In this study most of the patients taking
ASA (71%) were taking a dose of 325 mg/d. However, we
have shown a dose-related effect of ASA on the improve-
ment in LVEF seen with beta-blockers. Although low doses
of ASA are believed to have a short-lived effect on endo-
thelial prostacyclin production, ASA in doses of 40 to
80 mg given to patients 12 to 16 h prior to coronary bypass
surgery suppresses aortic prostacyclin production by 35% to
38% (34). In addition, the effect of low doses of ASA on
prostacyclin production and the duration of that effect may
be different in nonvascular endothelial tissues (35). Myo-
cardial cells and endocardial endothelial cells are known to
synthesize PGs PGI2, PGE2 and PGF2, but the duration
of effect of ASA on cyclo-oxygenase and the dose of ASA
required for this effect in these tissues are unknown (36,37).
A recent study in human subjects with heart failure dem-
onstrated that even 75 mg of ASA blocked arachidonic
acid–induced vasodilation (38). Thus, substantial data indi-
cate that even low-dose ASA could influence some of the
potential mechanisms of myocardial remodeling.
Consistency of the findings. The findings of this article
are strengthened by their consistency. The clinical effect of
a loss of 2 EF units of change in LVEF, for a dose of
325 mg/day of ASA, was seen repeatedly: across etiology
(ischemic, nonischemic), across beta-blocker treatment
(placebo, low-dose, mid-dose, high-dose) and across type of
analysis (bivariate, multivariate). The strongest predictors
influencing the change in LVEF with carvedilol were
carvedilol dose, ASA dose and etiology of heart failure.
Carvedilol dose and ischemic etiology have both been
shown to be important predictors of the improvement in
LVEF with beta-blockers (14,39). Baseline LVEF, baseline
HR and coumadin were weaker predictors. Baseline LVEF
and HR were shown to be similar predictors in a previous
analysis (30). Coumadin has not been reported to be a
predictor of change in LVEF. However, the statistical
strength of this association was relatively weak. The asso-
ciation cannot be explained by the greater coumadin use in
nonischemic patients, as coumadin in multivariate analysis
was found to be associated with less improvement in LVEF
with carvedilol, not more as would be expected if coumadin
identified nonischemic patients. Further study of the effects
of coumadin is clearly necessary.
Study limitations. This study is limited by its retrospective
nature. It is further limited by baseline differences between
ASA users and nonusers, particularly in age and etiology,
resulting in correlations among predictor variables. While
there was no MCL, multivariate analysis may not have
completely controlled these differences. Despite the small
number of subjects, highly significant results were found.
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